{
    "organizations": [],
    "uuid": "0fd198a2e6bb7e9626028ac410f699f17ca2fd43",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-moleculin-expands-leukemia-develop/brief-moleculin-expands-leukemia-development-portfolio-with-immuno-stimulating-stat3-inhibitor-idUSFWN1P50I4",
    "ord_in_thread": 0,
    "title": "BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 10, 2018 / 1:43 PM / Updated 25 minutes ago BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor Reuters Staff \nJan 10 (Reuters) - Moleculin Biotech Inc: \n* MOLECULIN EXPANDS LEUKEMIA DEVELOPMENT PORTFOLIO WITH IMMUNO-STIMULATING STAT3 INHIBITOR \n* MOLECULIN BIOTECH INC - EXPANDED COMPANYâ€˜S DEVELOPMENT PIPELINE FOR TREATMENT OF ACUTE MYELOID LEUKEMIA WITH AN IMMUNO-STIMULATING STAT3 INHIBITOR Source text for Eikon: Further company coverage:",
    "published": "2018-01-10T21:43:00.000+02:00",
    "crawled": "2018-01-10T16:03:01.039+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "expands",
        "leukemia",
        "development",
        "portfolio",
        "stat3",
        "inhibitor",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "moleculin",
        "biotech",
        "inc",
        "moleculin",
        "expands",
        "leukemia",
        "development",
        "portfolio",
        "stat3",
        "inhibitor",
        "moleculin",
        "biotech",
        "inc",
        "expanded",
        "company",
        "development",
        "pipeline",
        "treatment",
        "acute",
        "myeloid",
        "leukemia",
        "stat3",
        "inhibitor",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}